Integrated BioPharma, Inc. (INBP)
Oxford Ledge is still expanding full research coverage of INBP. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Integrated BioPharma manufactures and distributes vitamins and nutritional supplements to major customers under FDA-regulated conditions.
Source: 10-K (2025-06-30) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Entry into material agreement; Termination of material agreement; Financial statements and exhibits 2026-07-02
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-08
- 10-Q Quarterly financial report (unaudited) 2026-05-08
- 8-K Other material event; Financial statements and exhibits 2026-04-15
- 8-K Entry into material agreement; Financial statements and exhibits 2026-02-18
Source: SEC EDGAR.
Annual results
5 years of annual figures for INBP, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2026 | $43.9M | -$2.8M | -$0.09 |
| 2025 | $54.4M | $808,000 | $0.03 |
| 2024 | $50.3M | $112,000 | $0.00 |
| 2023 | $50.7M | -$34,000 | $0.00 |
| 2022 | $56.2M | $3.8M | $0.12 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for INBP. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open INBP in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.